SCHEMBL10275584

SCHEMBL10275584

CCOC(=O)Cc1c(O)[nH]c2c(-c3ccc(C(F)(F)F)cc3)c(C)nn2c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 7/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
NPSR1 Q6W5P4 1/20 0.44
HPGD P15428 5/20 0.42
ALDH1A1 P00352 4/20 0.42
GPR119 Q8TDV5 1/20 0.42
MAPT P10636 4/20 0.41
POLB P06746 1/20 0.41
HTT P42858 3/20 0.41
TRPM2 O94759 1/20 0.41
HSD17B10 Q99714 2/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10276177 0.84 MAPT (0.44) KDM4EL3MBTL1ALDH1A1GPR119MAPT
SCHEMBL10275463 0.81 GPR119 (0.44) SMN1; SMN2KDM4EL3MBTL1NPSR1HPGD
SCHEMBL10313511 0.78 GPR119 (0.43) KDM4EL3MBTL1ALDH1A1GPR119MAPT
SCHEMBL10275895 0.77 KDM4E (0.45) SMN1; SMN2KDM4EL3MBTL1HPGDALDH1A1
SCHEMBL10275766 0.75 MAPT (0.43) KDM4EL3MBTL1ALDH1A1GPR119MAPT
SCHEMBL10313817 0.75 SLC34A1 (0.42) KDM4EL3MBTL1HPGDALDH1A1GPR119
SCHEMBL10275634 0.75 GPR119 (0.42) KDM4EL3MBTL1HPGDALDH1A1GPR119
SCHEMBL10276317 0.73 ALDH1A1 (0.44) KDM4EL3MBTL1HPGDALDH1A1GPR119
SCHEMBL10275451 0.73 MAT2A (0.47) SMN1; SMN2KDM4ENPSR1HPGDALDH1A1
SCHEMBL10275704 0.72 PDE2A (0.43) SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 SMN1; SMN2 1771/4885KDM4E 3483/4885L3MBTL1 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.